Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

Roche - Basel

Roche drug fails in lung cancer trial

Damages prospects for onartuzumab

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

More woes for Daiichi as Ranbaxy units stop API shipments

Manufacturing problems continue to gather pace

- PMLiVE

Developing therapeutic cancer vaccines

Dendreon’s success has paved the way for new candidates

- PMLiVE

Lilly’s ramucirumab boosts survival in lung cancer

Late-stage trial backs regulatory prospects

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

- PMLiVE

Servier signs cancer collaboration with Cellectis

Will target leukaemia and five solid tumours

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

Debunking cancer myths

World Cancer Day seeks to challenge preconceptions

- PMLiVE

Treatment alone will not tackle cancer epidemic, says WHO

Burden will be highest in developing countries

- PMLiVE

Servier expands breast cancer partnership

Will build on deal with French cancer research centre Curie-Cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links